Senti Biosciences, Inc. (SNTI) fell 23.88 percent to $3.80, down $1.19 during Monday's trading, even after the company reported additional positive preliminary data from its Phase 1 trial of SENTI-202, an off-the-shelf CAR-NK cell therapy candidate for relapsed/refractory hematologic malignancies including AML.
The stock opened at $4.7600 and traded between $3.8100 and $4.9500 during the session on the Nasdaq. Volume reached 3.37 million shares, significantly higher than the average daily volume of 30,470. Senti Biosciences' 52-week range is $1.5200 to $16.9400.
The company plans to discuss the new data in a conference call and webcast scheduled for today.
For comments and feedback: editorial@rttnews.com